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We evaluated the performance of CRYPTO-LEX (Trinity Laboratories, Inc., Raleigh, N.C.), a new mouse
immunoglobulin M monoclonal antibody latex agglutination reagent which reacts with the capsular polysac-
charide of the four serogroups of Cryptococcus neoformans. This test was compared with CALAS (Meridian
Diagnostics, Cincinnati, Ohio) for the ability to detect cryptococcal antigen in serum and cerebrospinal fluid
(CSF). A total of 580 clinical specimens (327 serum and 253 CSF samples), primarily from human
immunodeficiency virus-infected patients, were tested in this study. Sixty-seven specimens (44 serum and 23
CSF samples) were positive for cryptococcal antigen with both tests, and 511 (282 serum and 229 CSF samples)
were negative. The two latex reagents agreed for 326 of 327 serum specimens (44 positives and 282 negatives).
One serum specimen with a titer of 1:2 was CALAS positive but CRYPTO-LEX negative. The titer correlation
coefficient for the two tests was 0.884 when two highly discordant serum specimens were eliminated from
analysis of the data. The two latex tests agreed for 252 of 253 CSF specimens (23 positives and 229 negatives).
One specimen with a titer of 1:2 was positive with CALAS and negative by CRYPTO-LEX. The correlation
coefficient of the two tests for CSF titers was 0.886. The sensitivity and specificity of CRYPTO-LEX were 97 and
100%, respectively, with a 99.6% correlation with CALAS. These data show that the performance of
CRYPTO-LEX is comparable to that of CALAS for detection of cryptococcal antigen in serum and CSF.
Cryptococcosis is a systemic infection caused by the encap-
sulated yeast Cryptococcus neoformans. The organism typically
initiates infection by gaining entrance to the lungs, and from
there, infection may rapidly disseminate to the brain and
meninges. Prior to the AIDS epidemic, disseminated crypto-
coccal infection occurred only sporadically, typically in patients
with sarcoidosis or lymphoma or in those receiving adrenal
corticosteroids (10). However, there has been a dramatic
increase in these cases since the 1980s, when AIDS became the
leading predisposing factor to the development of this disease.
Approximately 7 to 8% of human immunodeficiency virus
(HIV)-infected patients develop cryptococcal meningoenceph-
alitis, which often leads to death (6, 11, 13). C. neoformans is
now the pathogen most frequently isolated from cerebrospinal
fluid (CSF) at our institution. Traditionally, the diagnosis of
cryptococcosis has relied on culture of CSF or demonstration
of encapsulated yeast cells in India ink preparations of CSF.
Direct examination by India ink is a rapid but relatively
insensitive method. It is positive in at least 50% of cases of
cryptococcal meningitis in non-HIV-infected populations and
74 to 88% of cases in HIV-infected patients (5-7, 13, 24). In
addition, CSF chemistries and cell counts are often within
normal parameters, precluding the use of these methods as
rapid indicators of infection in HIV-infected individuals (6, 7,
13). Detection of C. neoformans capsular polysaccharide anti-
gen in CSF or serum has been established as a rapid and
sensitive method for the diagnosis of cryptococcosis, exhibiting
greater than 90% sensitivity (6, 12, 13, 23, 24). Early methods
for cryptococcal antigen detection included immunodiffusion,
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complement fixation, and latex agglutination (2-4, 16, 17, 19,
21). Latex agglutination has gained widespread appeal because
of its ease of use and greater sensitivity than the former
methods. Commercially available cryptococcal antigen detec-
tion systems utilize either agglutination with anticryptococcal
globulin-sensitized latex particles or enzyme immunoassay with
polyclonal antibody capture and monoclonal detection (14, 15,
18, 20, 22, 23). Commercial kits typically demonstrate 90 to
100% sensitivity and 97 to 100% specificity compared with
culture and clinical diagnosis (14, 15, 20, 22, 23). These antigen
detection systems can be quantitated and therefore used
prognostically and to monitor therapy (1, 6, 9-11, 24).
In this study, we compared the CALAS polyclonal latex
agglutination kit (Meridian Diagnostics, Cincinnati, Ohio), our
standard method for detection of cryptococcal antigen in
serum and CSF, with CRYPTO-LEX (Trinity Laboratories,
Inc., Raleigh, N.C.), a new monoclonal antibody-based latex
agglutination assay. We tested 253 CSF and 327 serum speci-
mens, primarily from HIV-infected patients suspected of hav-
ing systemic cryptococcal disease, for the presence of crypto-
coccal antigen. We stored 190 CSF and 232 serum specimens
at 4°C and tested them within 24 h of receipt with both CALAS
and CRYPTO-LEX. Retrospective analysis was performed
with CRYPTO-LEX on 63 CSF and 95 serum specimens
stored at -20°C. These specimens had been tested previously
with CALAS, and recorded results were used for comparison
with CRYPTO-LEX results.
The CALAS latex agglutination kit (Meridian Diagnostics)
was used in accordance with the instructions provided in the
package insert. Prior to testing, all serum samples were treated
with pronase for 15 min at 56°C and then boiled for 5 min. CSF
specimens were boiled for 5 min before testing. Specimens
demonstrating a 2+ or greater agglutination reaction were
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TABLE 1. Comparison of CRYPTO-LEX with CALAS for detection of cryptococcal antigen in serum and CSF
No. of CALAS-positive specimens No. of CALAS-negative specimens
CRYPTO-LEX result
CSF Serum Total CSF Serum Total
Positive 23 44 67 0 0 0
Negative 1 1 2 229 282 511
considered positive, and titers were then determined. The titer
was defined as the highest dilution which yielded a 2+
reaction. The CRYPTO-LEX latex agglutination assay (Trinity
Laboratories) utilizes a mouse immunoglobulin M (IgM)
monoclonal antibody with reactivity to a repeating epitope in
the capsular polysaccharide of C. neoformans. As stated by the
manufacturer, the reagent reacts with all four serogroups of C.
neoformans but not with rheumatoid factor since an IgM
antibody is used for detection (8). CRYPTO-LEX has been
demonstrated to cross-react with antigen from Trichosporon
beigelii, as do other cryptococcal antigen latex agglutination
tests (8). For CRYPTO-LEX, all CSF specimens were boiled
for 5 min. A 300-pu volume of each serum specimen was
treated with an equal volume of protease reagent supplied by
the manufacturer and then boiled for 10 min. Fifty microliters
of the treated sample (serum or CSF) was placed within a
circle on a black disposable card supplied with the kit. One
drop of latex sensitized with anti-cryptococcal IgM monoclonal
antibody was added to each sample. A control latex suspension
was not necessary in this assay. The latex-specimen mixture
was rotated for 5 min at 100 to 110 rpm and read immediately.
The titers of all positive specimens (1+ or greater) were
determined in the same manner as those of the CALAS-
positive specimens. Regression analysis and determination of
correlation coefficients for comparison of titers obtained with
the CALAS and CRYPTO-LEX latex tests were done by using
the LABSTAT statistical program (Prism Associates, Atlanta,
Ga.).
Of 580 specimens, 67 (44 serum and 23 CSF) tested positive
and 511 (282 serum and 229 CSF) tested negative with both
latex assays (Table 1), resulting in a 99.6% correlation between
the two tests. Two discrepant specimens (one serum and one
CSF) were CALAS positive and CRYPTO-LEX negative.
Both of these specimens had a titer of 1:2 and were from
patients with negative cryptococcal cultures. The sensitivity
and specificity of CRYPTO-LEX for all specimens (serum and
CSF) were 97 and 100%, respectively, with a positive predictive
value of 100% and a negative predictive value of 99.6%. There
was no significant difference in these values for either serum or
CSF or between refrigerated and frozen specimens. There was
no significant difference between CRYPTO-LEX titers ob-
tained with fresh or frozen specimens and CALAS titers. The
coefficient of correlation between titers determined with the
two assays was poor for serum (r = 0.253). However, when two
highly discordant serum specimens were removed from the
regression analysis, the correlation coefficient became 0.884.
Serum titers that differed by greater than twofold were ob-
tained with 11 of 44 specimens. The CALAS titers were higher
in five specimens, and the CRYPTO-LEX titers were higher in
six specimens. The coefficient of correlation between the two
assays for titers of cryptococcal antigen in CSF was 0.886. Of
23 CSF specimens, 22 exhibited titers which were within 1
dilution of each other.
Detection of cryptococcal antigen in serum and CSF has
become a routine procedure for the diagnosis of cryptococcosis
in HIV-infected patients with meningitis or fever of unknown
origin. In this study, we compared CRYPTO-LEX, a newly
developed latex agglutination test, with CALAS for detection
of C. neoformans capsular polysaccharide in serum and CSF.
CRYPTO-LEX utilizes latex particles sensitized with an IgM
monoclonal antibody. Multivalent binding between the IgM
antibody and the repeating epitope of the cryptococcal po-
lysaccharide provides increased stability of the antigen-anti-
body complex compared with polyclonal or monoclonal IgG
detection systems. Also, use of an IgM antibody effectively
eliminates false-positive reactions with rheumatoid factor,
thereby obviating the need for inclusion of a control latex in
the assay. No CRYPTO-LEX-positive, CALAS-negative reac-
tions were noted in this study; however, CRYPTO-LEX did
not detect two CALAS-positive specimens. The discrepant
specimens (one serum and one CSF) had titers of 1:2 and were
from patients with negative cryptococcal cultures. The discrep-
ant serum specimen was from a patient who had a cryptococcal
antigen titer in serum of 1:80 1 year prior to the initiation of
this study. The patient was receiving therapy and was asymp-
tomatic at the time of collection of the study specimen. This
specimen likely represented a false-negative CRYPTO-LEX
reaction. The discrepant CSF specimen was from a patient
with a positive CSF Venereal Disease Research Laboratory
result who was receiving treatment for secondary syphilis. This
patient had no previous specimens that were positive for C.
neoformans, and a CSF specimen submitted 5 months later was
negative for cryptococcal antigen. The initial CALAS-positive
CSF specimen was considered a false-positive result by the
physician. Such false-positive reactions with CALAS may be
due to the clarity of the agglutination reaction. It may be
difficult to determine the 2+ agglutination cutoff for a positive
CALAS result, and therefore, a 1+ reaction may be mistakenly
read as positive. The fact that any visible agglutination is
considered positive with CRYPTO-LEX eliminates the subjec-
tive determination of a 2+ threshold value for positivity. The
technologists who routinely read both the CALAS and
CRYPTO-LEX reactions found the CRYPTO-LEX results to
be much easier to interpret.
The CSF antigen titers obtained with CALAS and
CRYPTO-LEX were within 1 dilution in 96% (22 of 23) of the
specimens. The titers differed by more than twofold in 11
(25%) of 44 serum specimens. CRYPTO-LEX did not produce
characteristically higher or lower titers than CALAS. These
two tests cannot be used interchangeably for determination of
antigen titers, which is consistent with the results obtained in
previous comparisons of other latex agglutination assays (14,
15, 18, 20).
Two additional monoclonal antibody-based cryptococcal an-
tigen detection systems are commercially available. These tests
have an overall correlation of approximately 98% compared
with CALAS (14, 15, 20). Advantages and disadvantages of
these systems are mentioned here to provide a basis for
comparison with the new CRYPTO-LEX system. Pastorex
(Sanofi-Diagnostics Pasteur, Marnes-la-Coquette, France), a
latex agglutination assay, utilizes an IgG monoclonal antibody
for detection of cryptococcal polysaccharide (20). This test
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compared favorably with CALAS. However, since it also uses
IgG-based detection, it still necessitates the use of a control
latex reagent. The PREMIER (Meridian Diagnostics) enzyme
immunoassay for detection of cryptococcal polysaccharide
employs a polyclonal antibody capture system with monoclonal
detection (14, 15). The enzyme immunoassay does not require
enzymatic pretreatment of specimens, and it does not react
with rheumatoid factor. In comparisons with CALAS, it of-
fered the advantage of somewhat increased sensitivity but
false-positive enzyme immunoassay results were also noted
(14, 15).
Overall, the results obtained with CRYPTO-LEX correlated
well (99.6%) with those obtained with CALAS. The two tests
were similar in terms of specimen preparation and reaction
time. We conclude that CRYPTO-LEX is a rapid, reliable, and
cost-effective alternative assay for detection of cryptococcal
antigen in CSF and serum.
We thank Bruce Clinton of Trinity Laboratories, Inc., for kindly
providing the CRYPTO-LEX kits used in this study.
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